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Between January 1993 and February 1996, we performed 150 bilateral lung 
volume reduction procedures for patients with severe emphysema. Patients 
were selected on the basis of severe dyspnea, increased lung capacity, and 
a pattern of emphysema that included regions of severe destruction, 
hyperinflation, and poor perfusion. Twenty percent to 30% of the volume of 
each lung was excised with the use of a linear stapler and bovine pericardial 
strips attached to buttress the staple line. Patients were between 36 and 77 
years oicl, with an average 1-second forced expiratory volume of 25% of 
predicted, total lung capacity of 142% of predicted, and residual volume of 
283% of predicted. Ninety-three percent of patients required supplemental 
oxygen, Continuously or with exertion. All patients but one were extubated 
at the end of the procedure. The 90-day mortality was 4%. Hospital stay 
progressively decreased with experience, and for the last 50 patients the 
median hospital stay was 7 days. Prolonged air leakage was the major 
complication. Results at 6 months show a 51% increase in the 1-second 
forced expiratory volume and a 28% reduction in the residual volume. The 
Pao2 increased by an average of 8 mm Hg, and 70% of the patients who had 
previously required continuous supplemental oxygen no longer had this 
requirement. The improvements in measured pulmonary function were 
paralleled by a significant reduction in dyspnea and an improvement in the 
quality of life. Reevaluation at 1 year and 2 years after operation showed the 
benefit to be well maintained. We conclude that lung volume reduction 
offers benefits not achievable by any means other than lung transplantation 
for highly selected patients with severe emphysema. (J Thorac Cardiovasc 
Surg 1996;112:1319-30) 
C hronic obstructive pulmonary disease resUlting from emphysema is a major cause of morbidity 
and mortalityJ'  2As the disease progresses, physical 
activities become increasingly limited, and patients 
in advanced stages become dyspneic with minor 
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exertion or even at rest. Many patients require 
supplemental oxygen. The major therapeutic modal- 
ities consist of bronchodilator and antiinflammatory 
drugs,3, 4 directed at decreasing airway resistance, 
and antibiotics to treat acute and chronic infection. 
Pulmonary rehabilitation techniques and exercise 
training have produced Significant palliation. 5 Sup- 
plemental oxygen therapy for the hypoxemic patient 
improves exercise performance and improves sur- 
vival in patients with cor pulmonale. 6'7 Despite all 
available therapies, the course of the disease is one 
of progressive limitation, increasing dyspnea, and 
significant increase in overall mortality. After the 
1-second forced expiratory volume (FEV 0 falls 
below 30% of the predicted value, the overall sur- 
vival at 3 years is only 60%. 8, 9 
Emphysema interferes with respiratory function 
because of parenchymal destruction and changes in 
1319 
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Table I. Eligibility criteria for evaluation for lung 
volume reduction surgery 
Emphysema with hyperinfiation and heterogeneity (i.e., target 
areas) 
Marked physiologic mpairment (FEV 1 <35%) 
Marked restriction in activities of daily living despite maximal 
medical therapy 
Age younger than 75 years 
Acceptable nutritional status (70% to 130% of ideal body 
weight) 
Ability to participate in a vigorous pulmonary rehabilitation 
program 
No coexisting major medical problems that would significantly 
increase operative risk 
Willingness to undertake risk of morbidity and mortality associ- 
ated with lung volume reduction 
Abstinence from cigarette smoking (->6 months) 
the mechanics of respiration. The progressive loss of 
lung elastic recoil leads to a decrease in the expira- 
tory flow rate and to progressive overexpansion of 
the lung, with an increase in residual volume and 
total lung capacity. Because of the progressive in- 
crease in thoracic volume, chest wall and diaphrag- 
matic function become impaired, increasing the 
work of breathing. 
The lung volume reduction procedure is based on 
the proposals and the limited experience reported 
by Dr. Otto Brantigan more than 35 years ago. s° He 
suggested that excision of some of the most de- 
stroyed portions of the lung could improve elastic 
recoil, reduce airflow limitation, and improve the 
mechanics of respiration. His limited experience 
wi thuni latera l  ung volume reduction, combined 
with the radical hilar stripping that was then in 
vogue, produced subjective improvements in a num- 
ber of his patients. On the basis of Brantigan's 
proposals and our own observations of improved 
chest wall and diaphragmatic position after lung 
transplantation i patients with severe emphysema, 
we initiated a program for bilateral lung volume 
reduction in highly selected emphysema patients. 
This study was undertaken to evaluate the interme- 
diate-term results of this procedure at our center. 
Methods 
Patient population. Between January 1993 and Febru- 
ary 1996, 150 patients underwent bilateral lung volume 
reduction at the Washington University Medical Center. 
One hundred forty-nine procedures were carried out 
through a median sternotomy, and one procedure, in a 
patient who had previously undergone coronary bypass 
surgery, used bilateral muscle-sparing thoracotomies. One 
additional patient underwent median sternotomy for a 
Table I I . Reasons for declining patients for lung 
volume reduction surgery 
Diffuse disease (no target areas) 30% 
Insufficient thoracic distention 16% 
Age or associated medical problems 16% 
FEV1 is too good 8% 
Pleural disease 8% 
Better suited for lung transplantation 8% 
Paco 2 >55 (in association with other problems) 7% 
Marked kyphosis 4% 
Other 3% 
bilateral procedure, but extensive bilateral pleural adhe- 
sions were encountered and significant air leakage oc- 
curred after completion of volume reduction on the right 
side. Therefore the procedure was terminated without he 
contralateral reduction. This patient had a satisfactory 
result but is not included in this series. 
Eligibility criteria include significant dyspnea nd respi- 
ratory limitation despite maximum medical management, 
lung hyperinflation, and a favorable anatomic situation in 
which zones of relatively destroyed, hyperinflated lung 
coexist with other regions of lesser destruction. This 
pattern affords the opportunity of excising 20% to 30% of 
the volume of each lung, consisting of nonfunctional 
regions, to improve respiratory mechanics and distribu- 
tion of the ventilation to the remaining lung. Several 
patients with diffuse disease and severe hyperinflation are 
included in this series. 
The evaluation process, including physiologic and ra- 
diologic criteria, has been reviewed. TM 12 In summary, 
thoracic distention is evaluated by inspiratory and expira- 
tory chest radiographs, distribution of function by quanti- 
tative ventilation/perfusion lung scanning, and relative 
degree of parenchymal destruction i the various regions 
by computed tomography (CT) scanning of the chest. 
Eligibility criteria are summarized in Table I. None of 
these criteria was considered absolute, and exceptions 
were made for individual circumstances. 
Approximately 80% of patients referred for this proce- 
dure were excluded from surgery, and the reasons for 
exclusion in more than 1000 evaluations are listed in Table 
II. Patients thought o be suitable candidates after initial 
review of records and on-site evaluation were enrolled in an 
exercise rehabilitation program for 6 weeks or longer. A final 
decision to proceed with the operation was made only after 
satisfactory completion of this program. The program in- 
cluded progressive exercise training and nutritional counsel- 
ing. Nutritional supplements or diets were prescribed as 
necessary to adjust body weight to within 20% of the 
calculated i eal value. The preoperative phase of pulmonary 
rehabilitation began as soon as the patient was accepted for 
lung volume reduction. The goals included optimizing exer- 
cise endurance and pulmonary hygiene. All patients were 
placed in pulmonary rehabilitation programs close to their 
homes. The local program was provided exercise guidelines 
that included having the patients exercise 5 to 7 days each 
week, with the goal of completing 30 minutes of continuous 
exercise, preferably on the treadmill. 
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Oxygen saturation of hemoglobin, as demonstrated by 
pulse oximetry, was maintained at 90% or greater with 
supplemental oxygen given as needed. The patient was 
provided as much oxygen as necessary to accomplish this 
task. On rare occasions oxygen concentrations approach- 
ing 100% delivered through a nonrebreather mask were 
used. The oxygen concentration was reduced immediately 
after the exercise. Treadmill speed was increased at 
subsequent exercise sessions, with the goal of attaining a
heart rate in the target range [(220 - age) x (75% to 
85%)]. The guidelines also included optimizing pulmo- 
nary hygiene as necessary with the use of arm and leg 
weights to strengthen extremities and doing arm ergom- 
etry for 5 to 10 minutes to train the upper extremities, with 
resistance added if tolerated. The local pulmonary reha- 
bilitation therapist was asked to send a facsimile of an 
exercise summary sheet to the lung volume reduction 
center every 2 weeks to determine the patient's progress 
and allow us to suggest changes to optimize the training 
program. 
The physiologic profile of patients undergoing this 
procedure is shown in Table III. Pulmonary function 
studies were measured with a Medgraphics 1085 appara- 
tus (Medical Graphics Corp, St. Paul, Minn.) before and 
after administration of aerosolized albuterol. The highest 
values obtained for forced vital capacity (FVC) and FEV 1 
were chosen for data analysis. Lung volumes were mea- 
sured with a Medgraphic 1085 plethysmograph. Oxygen 
requirement at rest was defined as a requirement for 
supplemental 02 to maintain oxygen saturation at 88% or 
better while at rest (NELLCOR N10 pulse oximeter, 
Nellcor Inc., Pleasanton, Calif.). Oxygen requirement with 
exercise was defined as the maximum amount of supple- 
mental oxygen required to maintain saturation at 90% or 
better during the 6-minute test. Dyspnea was quantified by 
the modified Medical Research Council (MRC) of Great 
Britain Dyspnea Scale 13 and the Mahler Dyspnea Index. ~4 
The modified MRC scale has five grades that describe the 
activity that provokes dyspnea; lower numbers correlate 
with less dyspnea. On the Mahler index, functional im- 
pairment is graded at baseline, but in contrast o the 
MRC, higher numbers correspond to less dyspnea. A 
transition index was used to assess changes from the 
baseline value at a later date. 
The typical patient experienced dyspnea t rest or with 
only mild exertion. Taking a shower, walking stairs, going 
shopping, and even getting dressed were associated for 
most patients with significant dyspnea that limited or 
prohibited the activity. Quality-of-life assessment was made 
by using two instruments, the Nottingham Health Profile 15 
and the Medical Outcomes Survey-Short Form 36.16 
Statistical analysis. Pulmonary function data were an- 
alyzed with paired Student's t test. Quality-of-life ques- 
tionnaires were analyzed with repeated measures of anal- 
ysis of variance and Tukey's pairwise comparisons to 
examine significant time effects. 
Operative technique. A left-sided double-lumen tube 
was used to provide isolated ventilation to either lung. 
Before induction of anesthesia,  thoracic epidural cath- 
eter was placed under fluoroscopic guidance. This was 
used to reduce the amount of narcotic required intraop- 
eratively and to provide optimal postoperative pain relief 
Table I I I .  Physiologic profile of 150 bilateral ung 
volume reduction patients 
Characteristic Mean 
Age (yr) 61 (range 36 to 77 yr) 
FEV~ L (% pred) 0.70 (25%) 
FVC L (% pred) 2.5 (70%) 
TLC L (% pred) 8.3 (142%) 
RV L (% pred) 5.9 (283%) 
Pao 2 (mm Hg) 62 (range 36 to 109) 
Paco2 (ram Hg) 42 (range 28 to 70) 
02 required at rest (% of patients) 54% 
02 required with exercise (% of pa- 93% 
tients) 
Steroid dependent (% of patients) 47% 
FEV1, Forced expiratory volume in 1 second; pred, predicted; TLC, total 
lung capacity; RV, residual volume; Pa, arterial partial pressure. 
with a minimal need for narcotics or respiratory depres- 
sants. The technique was designed to permit extubation at 
the end of the procedure, and this goal was accomplished 
for all patients, except one patient who was successfully 
extubated the following morning. The anesthetic manage- 
ment used for these patients has been described else- 
where. 17 
The operative technique has evolved over the past 3 
years. A linear stapler was used to excise the desired 
portions of the lung. In the first several patients, intraop- 
erative air leaks were apparent at the proximal staple line 
when reexpansion of the lung caused tears in the visceral 
pleura at the staple puncture sites. This finding was 
associated with prolonged postoperative air leaks. The 
technique of reinforcing the staple line with strips of 
bovine pericardium (Peri-strips, Bio-Vascular, Inc., St. 
Paul, Minn.) attached to the surfaces of the stapler before 
its application virtually eliminated air leakage at the staple 
line. This technique has previously been reported. 18 In the 
early part of this series, multiple independent wedge 
excisions were performed. However, the intervening 
pleura between such staple lines was often tense and 
subject o injury and rupture. To avoid this problem most 
resections are now performed with a continuous line of 
excision with successive application of the linear stapler. 
This operative technique has been reported elsewhere. 19
In 15 patients (10%), a complete anatomic lobectomy 
was used as part of the volume reduction procedure. 
Indications included known lung cancers in two and 
intraoperative findings of complete lobar destruction with 
a technically favorable situation for a lobectomy in the 
remaining patients. 
The major focus of disease in most patients was in the 
upper lobes, in keeping with the known pattern of centri- 
lobular emphysema in smokers. However, the region of 
most severe destruction in 18 patients was in the lower 
lobes, including 11 with known cq-antitrypsin deficiencies 
and 7 with normal enzyme levels. 
A residual space at the apex of the chest is not 
uncommon after the volume reduction procedure. We 
have often created an apical pleural tent so that parietal 
and visceral pleura can be in apposition, even if the 
residual lung fails to expand sufficiently to completely fill 
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Fig. 1. Kaplan-Meier survival curve for 150 patients after 
lung volume reduction. Survival is 93% at 1 year and 92% 
at 2 years. 
Hospital Length of Stay 
0-50 51-100 101-150 
Patients in Consecutive Order 
Fig. 2. Mean and median hospital stay for successive 
groups of 50 patients after bilateral ung volume reduc- 
tion. 
the chest. Although we have not evaluated the value of 
such a procedure in a randomized fashion, creation of a 
pleural tent is recommended when a sizable apical space 
remains at the end of the procedure. Two 28F chest ubes 
are placed in each pleural space. Tubes are brought out 
through the upper abdomen in a subxiphoid position. 
Our postoperative management was previously re- 
viewed. ~9 The most significant change during the course of 
this series was the avoidance of suction on the chest ubes 
in the postoperative period. All tubes are attached to a 
water-seal drainage system. Suction is applied only if the 
postoperative chest x-ray film reveals a pneumothorax 
greater than 30%; the underlying lung appears restricted 
or compressed, as evidenced by increased ensity on the 
x-ray film; or marked subcutaneous emphysema develops. 
Only 10 (20%) of the last 50 patients required chest tube 
suction at any time in the postoperative period. If a 
modest air leak persisted beyond the first 4 to 5 postop- 
erative days, the chest tube was connected to a Heimlich 
valve to facilitate patient mobility and discharge from the 
hospital. 
The continuous epidural administration ofbupivacaine, 
initiated intraoperatively, was continued in the recovery 
room, and a patient-controlled analgesia system (Baxter 
Healthcare Corp., Deerfield, Ill.) that delivered morphine 
sulfate (80 mg/40 ml) was initiated. Several hours later, if 
further pain control was required, ketorolac was adminis- 
tered systemically, with an initial dose of 30 mg followed 
by 15 to 30 mg every 6 hours for 48 hours. The sympa- 
thectomy effect frequently associated with the epidural 
bupivicaine was counteracted as necessary with a contin- 
uous infusion of phenylephrine for 24 to 48 hours. Anti- 
biotics, usually a cephalosporin, were administered intra- 
venously for 5 days on a routine basis. Antibiotic coverage 
was broadened at the first suggestion of pulmonary infec- 
tion. A team of chest physiotherapists supplemented the 
efforts of the experienced thoracic surgical nurses to 
provide vigorous chest physiotherapy and early ambula- 
tion. Patients began ambulation on a mobile treadmill 
brought to the bedside on the day after the operation. 
This permitted early ambulation of the patient without he 
need to provide portable oxygen and monitoring equip- 
ment or to disconnect the patient from the many attach- 
ments. Despite an intensive program of chest physiother- 
apy, we found it useful to insert a minitracheostomy tube 
(Mini-Trach II, Portex, Keene, N.H.) for tracheal suction, 
because many of these patients had thick secretions and a 
feeble cough. In the last 50 patients in this series, mini- 
tracheostomy was used in 1] (22%). 
Results 
Morbidity, mortality, and complications. Opera- 
tive mortality was 4% (6 patients) and included all 
deaths from any cause occurring within 90 days of 
operation or at a later date if the patient was never 
discharged from the hospital or a chronic care 
facility. Late deaths were defined as any death 
occurring more than 90 days after the procedure for 
patients who had been discharged from hospital or a 
chronic care facility. Four such late deaths occurred 
in this series: one at 92 days and one at 270 days, 
both of pneumonia; one at 235 days of a stroke; and 
one at 13 months of respiratory failure. Mean 
follow-up time for survivors was 14 months and the 
median follow-up time 13 months. Actuarial sur- 
vival, shown in Fig. 1, and was 93% at 1 year and 
92% at 2 years. 
With experience and the changes in operative 
technique and postoperative management previ- 
ously outlined, postoperative hospital stay progres- 
sively diminished, as illustrated in Fig. 2. All patients 
were discharged to their homes or to a hotel or 
self-care lodging facility if remaining in the St. Ix)uis 
area for an additional week of observation and 
exercise training. For the group of 150 patients, the 
mean postoperative hospital stay was 13.5 days, with 
a median of 10 days. For the last 50 patients in this 
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Fig. 3. Histogram of postoperative hospitalization for the 
last group of 50 patients after bilateral lung volume 
reduction. 
series, the mean hospital stay was 10 days, with a 
median of 7 days (Fig. 3). Of these 50 patients, 54% 
were discharged within 7 days and 67% within 9 days 
after the operation. Four patients with prolonged air 
leakage returned to their home cities with chest 
tubes and Heimlich valves in place. These tubes 
were removed at 18, 35, 37, and 38 days postopera- 
tively. 
The significant hospital complications are listed in 
Table IV. Reexploration for air leakage occurred 
early in the series, when continuous and progres- 
sively increasing levels of chest suction were used to 
eliminate or reduce air spaces. No reexploration for 
air leakage or space problems has occurred in the 
last 75 patients. The duration of prolonged air 
leakage has diminished with avoidance of routine 
chest ube suction. In the last 50 patients, persistent 
air leakage (>7 days) occurred in 18 patients (36%). 
Eleven patients required institution of mechanical 
ventilatory assistance at some time during their 
hospital stay. The duration of intubation ranged 
from 1 to 115 days. Five patients progressed to 
tracheostomy, and three of these ultimately died in 
the hospital. 
Functional results. Median follow-up time was 
415 days. Clinical follow-up information was avail- 
able for all surviving patients, and postoperative 
measurement of pulmonary function at 3 or 6 
months was available for all but 1 of the 127 patients 
who survived 6months or longer after the operation. 
After lung volume reduction, maximum improve- 
ment in measured lung function appeared to occur 
between 3 and 6 months preoperatively. Table V 
demonstrates the improvement seen in spirometry, 
Table IV. Hospital complications for 150 patients 
Complication Number of patients (%) 
Prolonged air leak (>7 days) 69 (46) 
Pneumonia 17 (11) 
Mechanical ventilation 11 (7) 
Reoperation 9 (6) 
Air leak 6 
Bleeding 2 
Space problem 1 
Tracheostomy 5 (3.3) 
Myocardial infarction 2 (1.3) 
Cardiac arrest 2 (1.3) 
Cecal perforation 2 (1.3) 
Bleeding into pleural tent 2 (1.3) 
lung volumes, and gas exchange 6 months after the 
procedure. The FEV 1 increased by an average of 
51%, the residual volume declined by 28%, and the 
mean Po 2 increased by 8 mm Hg. Seventy percent of 
the patients who required continuous oxygen admin- 
istration preoperatively were relieved of this neces- 
sity. Fifty-two percent of the patients who formerly 
required supplemental oxygen with maximum exer- 
tion required none at 6 months. This requirement 
was determined uring the most vigorous pace of 
walking possible. Many patients who require oxygen 
under those circumstances do not require oxygen 
during routine, submaximal exertion. Overall func- 
tional improvement was measured with the 
6-minute walk test. The results are shown in Table 
VI. Exercise capacity was significantly improved by 
the rehabilitation program, as has previously been 
demonstrated. 2° After the procedure there was a 
further significant increase in overall performance. 
Oxygen requirements during exercise increased ur- 
ing the preoperative r habilitation phase because of 
the higher achievable level of activity without con- 
comitant improvement in pulmonary function. After 
surgery, oxygen requirements during exercise dimin- 
ished significantly despite further significant in- 
creases in exercise capacity. 
Functional results 
Dyspnea. The level of dyspnea, as subjectively 
assessed by the patient, is depicted in Table VII. It 
was evaluated with the MRC scale and the dyspnea 
index of Mahler. Both showed a significant reduc- 
tion of dyspnea t 6 months. 
Quality of life, as assessed by the Medical 
Outcomes Survey-Short Form 36 and the Notting- 
ham Health Profile, was evaluated when the pa- 
tient was initially seen, after the preoperative 
rehabilitation program, and at intervals during the 
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Table V. Results at 6 months for 101 patients 
Characteristic Preoperative value Postoperative value Change 
FEV l L (% pred) 0.70 (25%) 1.06 (38%) 
FVC L (% pred) 2.5 (69%) 3.0 (87%) 
TLC L (% pred) 8.4 (143%) 7.2 (125%) 
RV L (% pred) 6.0 (288%) 4.3 (205%) 
Pao2 (mm Hg) 62 70 
Paco 2 (mm Hg) 43 39 
02 required at rest (% of patients) 52% 16%* 
02 required with exercise (% of patients) 92% 44%* 
Six-minute walk (ft) 1125 1311" 
Steroid dependent (% of patients) 49% 18%* 
~51%* 
~20%* 
+14%* 
$28%* 
78" 
$4* 
FEV1, Forced expiratory volume in 1 second; pred, predicted; FVC, forced vital capacity; TLC, total ung capacity; RV, residual volume; Pa, arterial partial 
pressure. 
*p < 0.001. 
Table VI. Six-minute walk 
Preoperative Postoperative 
Before rehab After rehab 3 rno 6 mo 
Number of patients 148 150 81 94 
Distance 856 1110 1280 1316 
Percent of patients 82% 95% 47% 43% 
requiring 02 
Table VII. Subjective assessment of dyspnea by the 
Medical Research Council Scale and Mahler Index 
Preoperative 
Postoperative 
Scale Before rehab After rehab (6 mo) 
Medical Research Council 2.9 2.8 1.2 
Mahler Dyspnea Index 0.92* 0.83t 2.2t 
(functional impairment) 
*Baseline index. 
tTransitional index. 
postoperative period. Only physical mobility, en- 
ergy, and vitality showed improvement during the 
preoperative r habilitation phase. Six months af- 
ter the operation, there was further statistically 
significant improvement (p < 0.05). In these same 
parameters and in the other parameters listed in 
Table VIII. 
One question contained in the Medical Outcomes 
Survey-Short Form 36 questionnaire asks how the 
patient views his or her overall health status com- 
pared with 1 year earlier. The responses for 108 
patients 6 months after the procedure are shown in 
Table IX. Ninety-eight percent of patients felt better 
after surgery compared with 1 year earlier. 
Intermediate term results. Of the 76 patients fol- 
lowed 1 or more years after the operation, 56 had 
pulmonary function measured at 6 months and at 1 
Table VIII. Quality of life: items showing 
improvement a 6 months after lung 
volume reduction 
Physical mobility* 
Energy* 
Emotional reaction 
Job or work 
Looking after home or home life 
Sex life 
Interests & hobbies; enjoyment of holidays 
Sleep 
Vitality* 
Physical functioning 
General health 
Social functioning 
Mental health 
*Changed to a significant degree (p < 0.05) during preoperative pulmo- 
nary rehabilitation, with further increase at 6 months postoperatively. 
Table IX. Medical Outcome Survey--Short Form 
36: response of 108 patients 6 months after lung 
volume reduction 
Answer* Patients responding (%) 
Much better 78 
Somewhat better 20 
About the same 1 
Somewhat worse 1 
Much worse 0 
*Question: compared with 1 year ago, how would you rate your health in 
general now? 
year. These data, shown in Table X, indicated that 
the initial benefit was maintained at 1 year. 
Our initial report 21 presented our early experi- 
ence with 20 patients. These 20 patients have been 
followed for a minimum of 24 months (range 25 to 
39 months; mean 30 months). At last follow-up all 
patients till considered themselves to be signifi- 
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Table X. Results of lung volume reduction for 56 patients 
Characteristic Preoperative value Value at 6 months Value at 1 year 
FEV 1 g (% pred) .69 (24%) 1.1 (38%) 1.0 (36%) 
FVC L (% pred) 2.4 (67%) 3.0 (87%) 3.0 (85%) 
TLC L (% pred) 8.1 (139%) 7.1 (123%) 7.3 (125%) 
RV L (% pred) 5.7 (283%) 4.1 (201%) 4.3 (208%) 
Pao2 (mm Hg) 63 72 71 
Paco z (ram Hg) 43 38 37 
02 required at rest (% of patients) 58% 9% 16% 
0 2 required with exercise (% of patients) 92% 38% 51% 
Six-minute walk (ft) 1150 1362 1357 
Steroid dependent (% of patients) 53% 17% 19% 
FEV1, Forced expiratory volume in 1 second; pred, predicted; FVC, forced vital capacity; TLC, total ung capacity; RV, residual volume; Pa, arterial partial 
pressure. 
Table XI. Results of the initial 20 patients 
Characteristic Preoperative value Value at 1 year Most recent value* 
FEV 1 g (% pred) .83 (27%) 1.33 (45%) 1.25 (42%) 
FVC L (% pred) 2.6 (69%) 3.2 (88%) 3.3 (87%) 
TLC L (% pred) 8.4 (141%) 7.7 (131%) 7.6 (127%) 
RV L (% pred) 5.9 (291%) 4.4 (212%) 4.4 (212%) 
Pao2 (mm Hg) 64 73 73 
Paco2 (ram Hg) 44 37 39 
02 required at rest (% of patients) 26% 0% 0% 
02 required with exercise (% of patients) 84% 5% 32% 
Six-minute walk (ft) 1205 1475 1481 
Steroid dependent (% of patients) 42% 6% 11% 
FEVI, Forced expiratory volume in 1 second; pred, predicted; FVC, forced vital capacity; TLC, total ung capacity'; RV,, residual volume; Pa, arterial partial 
pressure. 
*Patients were followed for at least 24 months. 
cantly improved over their preoperative status. 
The most recent follow-up data on these patients 
are shown in Table X! and confirm persistent 
objective benefit at 2 years. 
Discussion 
Our original report of bilateral lung volume re- 
duction surgery in 20 patients howed encouraging 
early results. 21 Subsequent experience has con- 
firmed the benefit achieved with this procedure in 
selected patients and has indicated that subjective 
and objective improvement persist for at least 2 
years. It is assumed that the progressive deteriora- 
tion in lung function known to occur over time with 
emphysema will continue, but many patients con- 
tinue to exhibit subjective and objective benefit, and 
five of the initial patients who have been followed 3 
or more years show well-sustained benefit. 
We consider the preoperative r habilitation pro- 
gram to be essential for three reasons. First, a 
decision to operate should only be made after 
optimum medical management has proved insuffi- 
cient. Second, the improved stamina nd nutritional 
status facilitates postoperative r covery. It has not 
been uncommon for patients who are initially totally 
wheelchair dependent toprogress to the point of 30 
minutes of continuous exercise on a treadmill at 1 
mile per hour for 30 minutes at the conclusion of the 
rehabilitation phase. Third, optimized preoperative 
medical management provides an appropriate base- 
line for evaluation of the benefits produced by the 
operation. 
We use the median sternotomy because this ap- 
proach provides excellent bilateral exposure, per- 
mits a bilateral approach through single incision, 
and allows continuous surveillance of both pleural 
cavities throughout the procedure. In tandem with 
our analgesic protocol, we believe median sternot- 
omy is associated with minimum morbidity. It is the 
ultimate muscle-sparing incision, because none of 
the chest wall muscles is incised, retracted, or pen- 
etrated. No painful intercostal nerve injury can 
result from the operative approach or from chest 
tube placement sites located in the subxyphoid 
region. 
Miller and associates have reported an experience 
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Table XII. Results after unilateral lung volume reduction for 17patients 
Characteristic Preoperative value Value at 3 to 6 months Change p Value 
FEV 1 L (% pred) .81% (28%) 1.08 (39%) 
FVC L (% pred) 2.7 (75%) 3.1 (88%) 
TLC L (% pred) 8.7 (139%) 7.4 (125%) 
RV L (% pred) 6.0 (266%) 4.4 (193%) 
Pao2 (mm Hg) 63 71 
Paco2 (mm Hg) 41 39 
02 required at rest (% of patients) 53% 24% 
02 required with exercise (% of patients) 94% 71% 
Six-minute walk (ft) 1038 1134 
Steroid dependent (% of patients) 50% 36% 
I' 33% <.01 
" 15% <.05 
$15% <.01 
$ 27% <.001 
I' 8 <.05 
NS 
<.05 
FEVT, Forced expiratory volume in 1 second: pred, predicted: FVC. forced vital capacity; TLC, total ung capacity; RV, residual volume; Pa, arterial partial 
pressure. 
with bilateral volume reduction similar to our own. 22 
Several other teams have reported their experience 
with volume reduction conducted by a unilateral 
thoracoscopic approach. The results confirm the 
benefits of the volume reduction concept, although 
objective improvement of a lesser magnitude has 
generally been accomplished with this unilateral 
approach. 23-2~ As a result, a bilateral thoracoscopic 
approach as been proposed at some centers. Our 
own experience includes 24 cases of unilateral vol- 
ume reduction, all undertaken because of contrain- 
dications to a bilateral procedure or because of a 
marked discrepancy in the degree of emphysema- 
tous changes in the two lungs. A muscle-sparing 
thoracotomy approach was used in these 24 patients. 
None of these patients has died, and significant 
benefit has been achieved, although of lesser mag- 
nitude than that achieved with the bilateral proce- 
dure (Table XII). 
We have specifically excluded from this report 
patients who underwent excision of giant bullae. 
During the period in which we performed the 150 
bilateral and 24 unilateral lung volume reduction 
procedures, only 9 patients have undergone bilateral 
giant bullectomy as indicated by the standard selec- 
tion criteria, which are giant space-occupying bullae 
in the presence of "relatively normal underlying 
compressed lung," as reported by Connelly and 
coworkers 26 in 1989. Despite the heightened interest 
in operations for emphysema, the relatively small 
number of patients referred for this condition em- 
phasizes the relative rarity of this entity. 
Two of the major issues that remain unresolved 
for the lung volume reduction procedure are how to 
select appropriate candidates and how to assess and 
interpret the results. We continue to be quite con- 
servative in our selection process, requiring signifi- 
cant functional limitation, marked thoracic disten- 
tion, and a favorable anatomic situation that permits 
excision of areas of marked estruction while retain- 
ing regions with lesser disease. With some excep- 
tions, we have excluded the much greater propor- 
tion of patients whose emphysema is rather 
uniformly distributed. Although several such pa- 
tients with satisfactory results are included in this 
series, it remains our assumption that the magnitude 
of impro'cement and the duration of benefit are 
related to the amount of lung with minimal to 
moderate disease that remains at the end of the 
procedure. To prove whether this assumption is
correct would require further experience with liber- 
alized selection criteria. 
Objective valuation of the degree and pattern of 
lung destruction remains imprecise. Despite consid- 
erable experience, our selection process admittedly 
contains a significant subjective component. Tech- 
niques are available to objectively quantify the de- 
gree and distribution of lung damage, such as high- 
resolution CT scan or quantitative CT in which a 
computerized program breaks down each lung slice 
into small pixels and analyzes each pixel for lung 
density. Such an analysis is capable of expressing the 
percentage of lung in each region that has severe, 
moderate, or minimal destruction. However, this 
technique is of more theoretical than practical 
value. 
In the current series, the most severely diseased 
lung usually was in the upper lobes, consistent with 
the known distribution of centrilobular emphysema 
in smokers. However, the most severe areas of 
destruction were located in the lower lobes of 18 
patients. Eleven had oq-antitrypsin deficiency, and 
seven did not. In these 18 patients the mean im- 
provement in FEV 1 has been 27%, the reduction in 
residual volume was 28%, and the increase in Pao 2 
was 5 mm Hg. These values are significantly less 
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than for the overall series, but nonetheless most of 
these patients have experienced significant func- 
tional improvement. 
The physiologic alterations responsible for the 
subjective and functional improvement observed 
after lung volume reduction remain unclear. There 
is often a lack of correlation in the degree of 
objective improvement achieved with each of the 
parameters. For any individual patient a minor 
increase in the FEV1 may be associated with a 
marked reduction in residual volume or with a very 
significant increase in the Pao 2. The overall benefit, 
as perceived by the patient, occasionally correlates 
poorly with the changes in physiologic measure- 
ments. However, the significant improvement seen 
in virtually all objective parameters measured in the 
group as a whole confirms that the benefits per- 
ceived by the patients are related to alterations 
produced by the procedure and not to a "sham 
effect," such as has been associated with numerous 
procedures performed earlier in this century and for 
which no demonstrable objective improvement 
could be documented. It is probable that the mea- 
surements we have made do not fully reflect the 
physiologic alterations brought about by the volume 
reduction procedure. More sophisticated studies, 
including measurement of he work of breathing and 
lung elastic recoil, have been made by others and 
have shown significant improvement after the oper- 
ation.22, 7, 28 
It has been suggested that the benefits achieved 
with the volume reduction procedure might accrue 
with a longer period of medical management and 
exercise rehabilitation and without an operative 
procedure. This is not the case. Each patient in this 
series served as his or her own control after receiv- 
ing maximum medical therapy as outlined in the 
American Thoracic Society Guidelines for the man- 
agement of chronic obstructive pulmonary disease. 29 
Other publications have documented that, notwith- 
standing the important benefits of a rehabilitation 
program in terms of increased mobility, stamina, 
and somewhat lessened yspnea, no improvement in 
measurable ung function or gas exchange occurred 
as a result of such a program. 9'30. 31 
A second question has been raised regarding the 
benefits of this procedure and the anticipated dura- 
tion of improvement achieved. Only complete 
follow-up of these patients will provide an answer. 
We hope with this procedure to "turn back the 
clock" by a number of years, while recognizing that 
the natural progression of the underlying process 
will continue. Whether this progression will be at 
the rate usually anticipated, slower because of im- 
proved lifestyle and medical management, or accel- 
erated because of the increased istending force on 
the residual diseased lung remains to be seen. 
We have not yet undertaken a formal study of the 
ongoing medical costs associated with the manage- 
ment of these patients, but our patients report hat 
visits to physicians and to emergency wards and the 
frequency of hospitalization have all been markedly 
diminished after the operation. Prolongation of life 
expectancy, although not the goal of lung volume 
reduction, appears to be another significant poten- 
tial benefit. Given the known correlation between 
FEV 1 and life expectancy, 8' 9 the mean improve- 
ment in FEV 1 demonstrated in this series may have 
a significant impact on the patients' longevity. The 
actuarial survival of 92% at 24 month s compares 
favorably with the anticipated death rate for patients 
with this degree of chronic obstructive pulmonary 
disease. However, this discrepancy may be related to 
a selection bias. Only a randomized, controlled 
study in which one half of the eligible patients are 
denied the volume reduction procedure for a num- 
ber of years would address this issue from a rigorous 
scientific standpoint. However, given the results 
achieved, the absence of any alternative therapy for 
these patients, and the fact that improved quality of 
life, not longevity, is the goal of this procedure, such 
a randomized trial poses serious ethical and moral 
issues. One method for evaluating the impact of 
lung volume reduction on life expectancy would be 
to compare results achieved after lung volume re- 
duction with the results for a cohort of patients who 
have been equivalently assessed for the procedure 
and found to be suitable in all respects except for the 
presence of a homogeneous pattern of destruction 
throughout the lungs. This would render them un- 
suitable for the volume reduction procedure by our 
current criteria. This cohort of patients would then 
be similar in all other respects, including severity of 
disease and absence of surgical contraindications, to 
the operative group and could serve as the best 
"natural history" control group. 
The relationship between lung volume reduction 
and lung transplantation for severe emphysema 
remains an important issue. Approximately two 
thirds of the patients in this series would not have 
qualified for lung transplantation because of age, 
coexisting medical problems, or insufficient severity 
of disease to justify transplantation. Similarly, ap- 
proximately two thirds of patients with obstructive 
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lung disease evaluated for lung transplantation at 
our center are considered unsuitable for lung vol- 
ume reduction, usually because of severe diffuse 
disease, associated small airways disease, or chronic 
infection. For the remaining patients, lung trans- 
plantation and lung volume reduction surgery can 
both be considered. Under these circumstances, the 
patients are informed ~f the risks and benefits of 
each procedure, and virtually all have chosen to 
undergo lung volume reduction, with the under- 
standing that this does not, in our opinion, preclude 
the chances for successful lung transplantation 
should it subsequently be deemed appropriate. 
At the time of this operation, 48 patients were 
considered suitable candidates for lung transplanta- 
tion on the basis of age, severity of lung function, and 
absence of apparent contraindications. None of these 
patients has received a lung transplant. Four of the 
patients in this series are actively listed for a lung 
transplantation, and eight others, who were listed for a 
transplant before their operations, are not currently 
considered active candidates because of the improve- 
ment in lung function after the reduction procedure. 
The lung volume reduction procedure has, tem- 
porarily at least, shifted a number of potential lung 
transplant recipients to an alternative procedure 
and has had the effect of increasing the number of 
available donors for patients suffering from other 
conditions, such as cystic fibrosis and pulmonary 
hypertension, for whom no alternative to transplan- 
tation exists. 
The risks of lung volume reduction for disabling 
emphysema should not be underestimated. Selec- 
tion, preparation, and postoperative care of these 
patients requires the coordinated activity of thoracic 
surgeons, anesthesiologists, pulmonologists, nurses 
experienced in the management of thoracic opera- 
tive patients, respiratory therapists, and others. In 
the absence of such a team approach, the morbidity 
and mortality associated with this procedure may 
well exceed that which we have reported. 
The lung volume reduction operation is logical, 
physiologically sound, and of proven benefit for a 
selected group of patients with no alternative ther- 
apy except lung transplantation, for which only a 
minority qualify. Further refinements in selection, 
operative technique, and postoperative manage- 
ment are anticipated. Accurate collection and re- 
porting of data from different centers will permit a 
comparison of different selection criteria, various 
operative approaches and techniques, and refine- 
ments in postoperative management. Current re- 
sults confirm an important albeit palliative role for 
the lung volume reduction procedure. 
We acknowledge the essential contributions made to 
the success of the lung volume reduction program by 
cardiothoracic anesthesia staff; the nursing service of the 
Division of Cardiothoracic Surgery; the chest physiother- 
apists and respiratory therapists, Dottie Biggar, RN, and 
the staff of the pulmonary rehabilitation team; Veronica 
Richardson Higgins, RN, the nurse coordinator; and 
many other members of the clinical team who provided 
experienced and tireless upport for the complicated care 
for this group of patients. We also acknowledge Ms. Kathy 
Stroud for her expert secretarial support. 
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Discussion 
Dr. John R. Benfield (Sacramento, Calif.). Out of 
respect for the Program Committee's desire not to have 
slides shown, I selected three slides that I am not going to 
show you. The first shows Joel Cooper at the Toronto 
General Hospital with his first successful lung transplan- 
tation patient and our Past President, Griff Pearson; the 
second is a letter I received from one of our patients. The 
patient says that he is a 73-year-old farmer who is back 
mowing hay and playing with his grandchildren after lung 
reduction. The third is a letter from that same patient o 
our Senator, Diane Feinstein, telling her that he cannot 
understand why the Health Care Financing Agency 
(HCFA) is not paying for lung reduction. I admire Joel 
Cooper's boundless energy and enthusiasm for the treat- 
ment of end-stage lung disease. 
The manuscript contains three points I would like to 
address. The first is that long-term outcome after lung 
volume reduction remains unknown. To this I say that the 
absence of such data is being ameliorated daily as short- 
term and intermediate-length outcome data accumulate. 
The second point is that there are no data about medical 
costs of emphysema with the lung volume reduction 
procedure compared with nonoperative management, in-
cluding pulmonary rehabilitation. To this I respond that 
we have eclipsed the past, when any new, beneficial health 
care measure was affordable. The need to contain cost 
requires that the value of lung volume reduction be 
measured by outcome divided by cost. We must determine 
whether the initial high cost of lung volume reduction is 
balanced by lesser long-term costs for medication and 
medical care for patients who are treated nonoperatively. 
The third point is that only about 20% of patients referred 
were accepted for operation. This underscores the need to 
undertake lung volume reduction as a team approach to 
avoid significantly higher morbidity and mortality than 
reported by the Washington University group. 
I close with a comment about the current lack of 
Medicare funding for lung volume reduction and with a 
question. The organizations that are the national forums 
for science and continuing education in thoracic surgery 
and in pulmonary medicine have advised HCFA that they 
do not consider lung volume reduction experimental. 
Hospital costs and professional fees therefore should be 
paid by Medicare when the procedure is offered to 
properly selected patients in centers that have track 
records uccessfully conducted, credible clinical research. 
There is no doubt that further esearch on the treatment 
of end-stage lung disease needs to be done and that lung 
volume reduction is a prime example for HCFA and the 
National Institutes of Health (NIH) to come together. 
HCFA should fund the patient care aspects of the treat- 
ment, and the NIH should support he needed research 
costs. Organized thoracic surgery spearheaded by the 
Society of Thoracic Surgeons and supported by the Amer- 
ican Association for Thoracic Surgery and respiratory 
medicine have stepped forward and offered help to HCFA 
and the NIH in this regard. I hope that these agencies will 
accept this offer on behalf of patients whose dyspnea 
deserves palliation. I believe that a randomized study in 
the early 1970s to compare aortocoronary b pass to the 
then best available nonoperative treatment would have 
resulted in far quicker acceptance of the operation than 
occurred. We are at a similar stage with lung volume 
reduction, because it remains possible and perhaps likely 
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that the benefits of lung volume reduction will prove to be 
transient. 
Dr. Cooper, would it not be best to proceed with a 
randomized, prospective evaluation of lung volume reduc- 
tion surgery compared with the best available pulmonary 
rehabilitation? 
Dr. Cooper. Thank you, Dr. Benfield. You raised the 
issue of values. The scientific issues, such as how does this 
operation work, and how long will it last, all require 
careful scrutiny and the usual process by which, over the 
years, we decide which therapies are or are not of value. I
believe these questions can be answered without random- 
ization. The issues of value, such as how much is it worth 
to feel better and how long does the patient have to feel 
better to make it cost effective, probably cannot be 
answered by a randomized trial. 
A randomized trial may not be the best approach for 
evaluating the medical benefits of the procedure. Lung 
volume reduction produces changes in FEV1, residual 
volume, and other objective measurements which cannot 
be achieved by any current nonsurgical treatment. Therein 
is the dilemma of denying it to patients for whom it is the 
only possible choice. I completely subscribe to careful 
scrutiny and evaluation, and I have no objection to any 
center conducting a compassionate and randomized trial 
as long as scientific evaluation isnot used as a disguise for 
rationing or access limitation to a procedure for which 
there is no alternative. 
Dr. Cecil C. Vaughn (Phoenix, Ariz.). I wish to comment 
on the technique of minimizing air leakage after the lung 
volume reduction procedure. I heartily endorse the need 
for staple line reinforcement and staple wedge resections 
of emphysematous lung. My colleagues and I use 
quadrangular sleeves of expanded polytetrafluoroethylene 
(PTFE)* that fit on the anvil and cartridge of the stapler. 
These sleeves have tear seams and grasping flaps at each 
end to facilitate removal of the excess PTFE after firing 
the stapler. These sleeves have been used in 21 open and 
thoracoscopic procedures at our center in Phoenix and at 
the University of Vienna, and they represent another 
technique for the reduction of air leak. 
Dr. Cooper, what has been your experience with bovine 
pericardium, and how long did bovine pericardium last 
after its application? 
Dr. Cooper. When we initially reported the use of 
bovine pericardium, we summarized many of the different 
patching techniques and buttressing techniques that have 
been documented by others over the years, and I suppose 
it is a matter of personal preference. I have had the 
opportunity to reexplore two patients a month or more 
after the initial procedures, and the bovine pericardium 
seemed totally inert and well incorporated. I can only 
judge it on the basis of previous tudies done during the 
last 10 or 15 years in whic.: many persons have studied the 
material as a bioprosthesis and as a tissue support. I agree 
with you that some form of buttressing the staple line in 
emphysematous lungs produces benefit, but I am con- 
cerned about he use of nonabsorbable foreign material in 
the potential presence of a prolonged air leak or pleural 
infection. 
* Seamguard Material, W. L. Gore & Associates, Inc., Newark, 
Del. 
